From 2022 April to 2024 August, retrospective analyses by multivariable logistic regression were conducted in 341 rheumatoid arthritis patients receiving rituximab (RTX), tofacitinib (TOF) or disease-modifying-anti-rheumatic drug (DMARD) alone therapy. Compared to DMARD alone or TOF treatment, RTX therapy had increased adjusted odds ratios of SARS-CoV-2-related hospitalization, pneumonia and mortality.